Mensch und Maschine Software SE

  • WKN: 658080
  • ISIN: DE0006580806
  • Land: Germany

Nachricht vom 21.10.2020 | 09:00

Mensch und Maschine Software SE discloses 9 months report 2020

DGAP-News: Mensch und Maschine Software SE / Key word(s): 9 Month figures
21.10.2020 / 09:00
The issuer is solely responsible for the content of this announcement.

Robust Q3 keeping profit on record path
- Record cash flows +53% to 195 Cents per share
- Strong Q4 + Record profit 2020 expected

Wessling, October 21, 2020 - After a very strong Q1 and a slower Q2 due to Corona, a robust Q3 helped Mensch und Maschine Software SE (MUM - ISIN DE0006580806), a CAD/CAM specialist company, achieve a double digit percentage increase over last year's nine months profit and cash flows records.

Sales grew to a 9M record EUR 180.61 mln (PY: 174.27 / +3.6%), with EUR 54.93 mln (PY: 54.73 / +0.4%) from M+M Software and EUR 125.68 mln (PY: 119.54 / +5.1%) from VAR Business. After a strong +24.5% in Q1, sales in Q2/Q3 came in -9.3%/-7.1% below the previous year.

Operating profit EBIT grew to EUR 21.76 mln (PY: 18.21 / +19.5%). Software contribution to this new 9M record was EUR 13.67 mln (PY: 12.20 / +12%), while the VAR Business achieved EUR 8.08 mln (PY: 6.02 / +34%). After +36% in Q1 and -3.7% in Q2, Q3 at +19.6% achieved a record EBIT. Net profit after minority shares increased by +14% to a record EUR 12.63 mln (PY: 11.04), or 75.3 Cents (PY: 65.6) per share. Operating cash flows jumped to a new record of EUR 32.73 mln (PY: 21.43 / +53%) or 195 Cents (PY: 127) per share.

After the robust business in Q2 and Q3 in spite of Corona, M+M Chairman Adi Drotleff expects "a strong Q4 with earnings around previous year's record level, so for 2020 new record earnings per share in the bandwidth of 107-118 Cents (PY: 99) can be expected, as well as 100-105 Cents dividend after 85 in PY. We are pleased to see cash flows already closing in on the 2 Euros level, indicating where we in the mid-term want to drive earnings per share, from 2021 onwards in steps of +18-24 Cents per year."
 


21.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021